tetano
Editor, Senior Moderator
Mult Scler
. 2022 Apr 27;13524585221089540.
doi: 10.1177/13524585221089540. Online ahead of print.
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Ana Zabalza[SUP] 1 [/SUP], Georgina Arrambide[SUP] 1 [/SUP], Susana Otero-Romero[SUP] 2 [/SUP], Agustín Pappolla[SUP] 1 [/SUP], Paula Tagliani[SUP] 1 [/SUP], Samuel López-Maza[SUP] 1 [/SUP], Simón Cárdenas-Robledo[SUP] 1 [/SUP], Juliana Esperalba[SUP] 3 [/SUP], Candela Fernández-Naval[SUP] 3 [/SUP], Monica Martínez-Gallo[SUP] 4 [/SUP], Mireia Castillo[SUP] 1 [/SUP], Mercè Bonastre[SUP] 1 [/SUP], Mireia Resina-Salles[SUP] 1 [/SUP], Jordina Bertran[SUP] 1 [/SUP], Marta Rodriguez-Barranco[SUP] 1 [/SUP], Pere Carbonell-Mirabent[SUP] 1 [/SUP], Marina Gonzalez[SUP] 5 [/SUP], Miguel Merchan[SUP] 5 [/SUP], Ana Quiroga-Varela[SUP] 6 [/SUP], Albert Miguela[SUP] 7 [/SUP], Imma Gómez[SUP] 7 [/SUP], Gary Álvarez[SUP] 5 [/SUP], René Robles[SUP] 8 [/SUP], Dúnia Perez Del Campo[SUP] 9 [/SUP], Xavier Queralt[SUP] 9 [/SUP], Maria José Soler[SUP] 10 [/SUP], Irene Agraz[SUP] 10 [/SUP], Fernando Martinez-Valle[SUP] 11 [/SUP], Breogán Rodríguez-Acevedo[SUP] 1 [/SUP], Luciana Midaglia[SUP] 1 [/SUP], Ángela Vidal-Jordana[SUP] 1 [/SUP], Álvaro Cobo-Calvo[SUP] 1 [/SUP], Carmen Tur[SUP] 1 [/SUP], Ingrid Galan[SUP] 1 [/SUP], Joaquín Castillo[SUP] 1 [/SUP], Jordi Río[SUP] 1 [/SUP], Carmen Espejo[SUP] 1 [/SUP], Manuel Comabella[SUP] 1 [/SUP], Carlos Nos[SUP] 1 [/SUP], Jaume Sastre-Garriga[SUP] 1 [/SUP], Lluís Ramió-Torrentà[SUP] 8 [/SUP], Mar Tintoré[SUP] 1 [/SUP], Xavier Montalban[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear.
Objectives: We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID).
Methods: Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers.
Results: 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies.
Conclusion: Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.
Keywords: COVID-19; SARS-CoV-2; cellular response; disease-modifying therapy; humoral response; multiple sclerosis.
. 2022 Apr 27;13524585221089540.
doi: 10.1177/13524585221089540. Online ahead of print.
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?
Ana Zabalza[SUP] 1 [/SUP], Georgina Arrambide[SUP] 1 [/SUP], Susana Otero-Romero[SUP] 2 [/SUP], Agustín Pappolla[SUP] 1 [/SUP], Paula Tagliani[SUP] 1 [/SUP], Samuel López-Maza[SUP] 1 [/SUP], Simón Cárdenas-Robledo[SUP] 1 [/SUP], Juliana Esperalba[SUP] 3 [/SUP], Candela Fernández-Naval[SUP] 3 [/SUP], Monica Martínez-Gallo[SUP] 4 [/SUP], Mireia Castillo[SUP] 1 [/SUP], Mercè Bonastre[SUP] 1 [/SUP], Mireia Resina-Salles[SUP] 1 [/SUP], Jordina Bertran[SUP] 1 [/SUP], Marta Rodriguez-Barranco[SUP] 1 [/SUP], Pere Carbonell-Mirabent[SUP] 1 [/SUP], Marina Gonzalez[SUP] 5 [/SUP], Miguel Merchan[SUP] 5 [/SUP], Ana Quiroga-Varela[SUP] 6 [/SUP], Albert Miguela[SUP] 7 [/SUP], Imma Gómez[SUP] 7 [/SUP], Gary Álvarez[SUP] 5 [/SUP], René Robles[SUP] 8 [/SUP], Dúnia Perez Del Campo[SUP] 9 [/SUP], Xavier Queralt[SUP] 9 [/SUP], Maria José Soler[SUP] 10 [/SUP], Irene Agraz[SUP] 10 [/SUP], Fernando Martinez-Valle[SUP] 11 [/SUP], Breogán Rodríguez-Acevedo[SUP] 1 [/SUP], Luciana Midaglia[SUP] 1 [/SUP], Ángela Vidal-Jordana[SUP] 1 [/SUP], Álvaro Cobo-Calvo[SUP] 1 [/SUP], Carmen Tur[SUP] 1 [/SUP], Ingrid Galan[SUP] 1 [/SUP], Joaquín Castillo[SUP] 1 [/SUP], Jordi Río[SUP] 1 [/SUP], Carmen Espejo[SUP] 1 [/SUP], Manuel Comabella[SUP] 1 [/SUP], Carlos Nos[SUP] 1 [/SUP], Jaume Sastre-Garriga[SUP] 1 [/SUP], Lluís Ramió-Torrentà[SUP] 8 [/SUP], Mar Tintoré[SUP] 1 [/SUP], Xavier Montalban[SUP] 1 [/SUP]
Affiliations
- PMID: 35475363
- DOI: 10.1177/13524585221089540
Abstract
Background: The effect of disease-modifying therapies on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is unclear.
Objectives: We aim to determine the immunological responses to SARS-CoV-2 in multiple sclerosis (MS) and anti-CD20-treated patients with other autoimmune diseases (AID).
Methods: Humoral and cellular responses we determined before and 30-90 days after vaccination in patients with MS and anti-CD20-treated patients with other AID in two Catalan centers.
Results: 457 patients were enrolled. Findings showed that humoral response decreased under anti-CD20s or sphingosine 1-phosphate receptor modulators (S1PRM) and with longer treatment duration and increased after 4.5 months from the last anti-CD20 infusion. Cellular response decreased in S1PRM-treated. Patients on anti-CD20 can present cellular responses even in the absence of antibodies.
Conclusion: Anti-CD20s and S1PRM modify the immunological responses to SARS-CoV-2 vaccines.
Keywords: COVID-19; SARS-CoV-2; cellular response; disease-modifying therapy; humoral response; multiple sclerosis.